Vincerx Pharma, Inc.
VINC
$0.055
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.71% | 7.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.54% | 5.80% | |||
| Operating Income | 17.54% | -5.80% | |||
| Income Before Tax | -1.93% | -333.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.93% | -333.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.93% | -333.79% | |||
| EBIT | 17.54% | -5.80% | |||
| EBITDA | 17.57% | -5.81% | |||
| EPS Basic | 28.56% | -312.70% | |||
| Normalized Basic EPS | 50.01% | -312.71% | |||
| EPS Diluted | 28.56% | -312.70% | |||
| Normalized Diluted EPS | 50.01% | -312.71% | |||
| Average Basic Shares Outstanding | 42.67% | 5.11% | |||
| Average Diluted Shares Outstanding | 42.67% | 5.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||